Clinical trials: No Disease
Hepatocellular Carcinoma
Study of NGR-hTNF as Single Agent in Patients Affected by Advanced or Metastatic Hepatocellular Carcinoma (HCC)
The main objective of the trial is to document the progression free survival (PFS) in advanced or metastatic hepatocellular carcinoma patients treated with NGR-hTNF as single agent.
- Trial name
- NCT00484211
- Testing
- NGR-hTNF
- Where
- 3 sites in Italy
- Volunteers
- 40 people
- Sponsor
- AGC Biologics S.p.A.
Histopathology
Histological Analysis of Bellafill Injected Tissue at Various Time Points
This is a prospective, in vivo proof-of-concept clinical study, where histopathologic examinations will be conducted at various timepoints following Bellafill injections.
- Trial name
- NCT03327311
- Testing
- Bellafill
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Suneva Medical, Inc.
Asthma
Study of the Effect of Mometasone Furoate/Formoterol (MF/F), Montelukast and Beclomethasone Dipropionate (BDP) on Plasma Cortisol Levels of Children 5-11 Years Old With Persistent Asthma (P05574)
The purpose of this study is to assess the effect of one of five possible study medications used in the treatment of asthma on blood plasma cortisol levels in children aged 5-11 years with persistent asthma.
- Trial name
- NCT01615874
- Testing
- MF/F Metered Dose Inhaler (MDI) 25/5 mcg, MF/F MDI 50/5 mcg, MF/F MDI 100/5 mcg
- Sponsor
- Organon and Co
COVID-19
A Study to Evaluate the Safety and Immunogenicity of Omicron COVID-19 Vaccine (Vero Cell), Inactivated in Population 18 Years Old of Age and Above
This is a non-randomized, open-label, externally controlled study to evaluate the safety and immnunogenicity of the Omicron COVID-19 Vaccine (Vero Cell), Inactivated in population aged 18 years old and above with no vaccination…
- Trial name
- COVID-19 (NCT05365724)
- Testing
- Omicron COVID-19 Vaccine (Vero Cell), Inactivated
- Where
- China
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- China National Biotec Group Company Limited
Hypogonadism, Hypogonadotropic Hypogonadism
A Study of the Efficacy and Safety of Corifollitropin Alfa (MK-8962) in Combination With Human Chorionic Gonadotropin (hCG) in Adult Men With Hypogonadotropic Hypogonadism (HH) (P07937)
This study will assess if corifollitropin alfa (MK-8962), when administered in combination with human chorionic gonadotropin (hCG), will increase testicular volume in men with HH who remain azoospermic after treatment with hCG…
- Trial name
- NCT01709331
- Testing
- Corifollitropin alfa, hCG
- Volunteers
- 18 people
- Sponsor
- Organon and Co
Hyperlipidemia
A Study to Determine the Bioequivalence of SCH 900068 Compared to Marketed Products (Protocol No. P07551)
The intent of this study is to demonstrate that single doses of the Final Market Image (FMI) ezetimibe/atorvastatin 10mg/10mg and 10mg/80mg fixed dose combination (FDC) tablets are bioequivalent to the same doses of ezetimibe…
- Trial name
- NCT01236430
- Testing
- Ezetimibe, Ezetimibe/atorvastatin 10mg/10mg FDC, Atorvastatin 10mg
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Organon and Co
no Specific Condition Targeted
Assessment of the Benefit of the Mobility Assistance System (SAM) on Transfer Independence for a Reimbursement Request
This is a randomized, cross-over, multi-center, intention-to-treat, open-label study to assess the impact of the SAM Ergonom light (SAM) device on independence when transferring from the supine to the sitting position at the edge…
- Trial name
- SAM-24 (NCT06698653)
- Testing
- SAM device (experimental): a removable structure, fixed to the horizontal frame of the medical bed, equipped with a handle to assist the sitting-up process, Over bed pole hoist (control device)
- Where
- 3 sites in France
- Volunteers
- 54 people
- Sponsor
- WINNCARE
Acute Myelogenous Leukemia
Aezea® (Cenersen) and Chemotherapy for AML Subjects ≥ 55 Years of Age With No Response to Frontline Induction Course
The purpose of this study is to assess whether treatment with cenersen in combination with 4 cycles of high and low-dose chemotherapy (idarubicin and cytarabine) improves the complete response rate in acute myelogenous leukemia…
- Trial name
- NCT00967512
- Testing
- cenersen, idarubicin, cytarabine
- Sponsor
- Eleos, Inc.
Glaucoma
Early Feasibility Study of the Brown Glaucoma Implant in Patients With Severe Visual Impairment or No Light Perceived
This is a prospective, non-randomized, single-arm early feasibility study to assess the safety and feasibility of lowering intraocular pressure with the Brown Glaucoma Implant.
- Trial name
- Early Bird (NCT03469297)
- Testing
- Brown Glaucoma Implant
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- MicroOptx
Cystic Fibrosis
A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation
The purpose of this study is to evaluate the efficacy and safety of VX-121/tezacaftor/deutivacaftor (VX-121/TEZ/D-IVA) in CF participants who are homozygous for F508del, heterozygous for F508del and a gating (F/G) or residual…
- Trial name
- NCT05076149
- Testing
- VX-121/TEZ/D-IVA, ELX/TEZ/IVA, IVA
- Where
- 170 sites in United States, Australia and 18 more
- Volunteers
- 597 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Solid Tumors
Dosimetry Study of I-131-CLR1404 in Patients With Relapsed or Refractory Advanced Solid Tumors
The purpose of the study is to investigate the safety, biodistribution, radiation dosimetry and pharmacokinetics of I-131-CLR1404.
- Trial name
- NCT00925275
- Testing
- I-131-CLR1404
- Where
- 4 sites in United States
- Volunteers
- 9 people
- Sponsor
- Cellectar, Inc
Ovarian Cancer
Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected
The objective of this study was to evaluate the efficacy and safety of alpelisib in combination with olaparib compared with single-agent cytotoxic chemotherapy in participants with platinum-resistant or platinum-refractory…
- Trial name
- NCT04729387
- Testing
- Alpelisib, Olaparib, Paclitaxel
- Where
- 93 sites in United States, Argentina and 24 more
- Volunteers
- 358 people
- Sponsor
- Novartis Pharmaceuticals
Tumors
Study of Dasatinib (BMS-354825) in Patients With Solid Tumors
The primary objective of this study is to determine the maximum tolerated dose (MTD) or the maximum administered dose (MAD) of Dasatinib (BMS-354825) in patients in Japan.
- Trial name
- NCT00339144
- Testing
- Dasatinib
- Where
- 2 sites in Japan
- Volunteers
- 16 people
- Sponsor
- Bristol-Myers Squibb
Lymphoma, Non-Hodgkin
Treatment With [90]Y-Ibritumomab Tiuxetan Versus no Treatment in Patients With Follicular Non Hodgkin Lymphoma (Stage III or IV) Having Achieved a Partial or Complete Remission After First Line Chemotherapy
The aim of the study is to test [90]Y-ibritumomab tiuxetan, a radioactive antibody, in patients with stage III or IV follicular lymphoma whose disease is in partial or complete remission after first line chemotherapy.
- Trial name
- NCT00185393
- Testing
- Zevalin ([90]Y-ibritumomab tiuxetan, BAY86-5128), no treatment
- Where
- 95 sites in Belgium, Canada and 11 more
- Volunteers
- 414 people
- Sponsor
- Bayer
Ventricular Tachyarrhythmia
NORDIC ICD (Cardioverter Defibrillator Implantation) Trial
The purpose of the NORDIC ICD study is to evaluate whether ICD implantation without intra-operative DF testing is non-inferior to ICD implantation with intra-operative DF testing regarding the efficacy of the first ICD shock for…
- Trial name
- NCT01282918
- Testing
- ICD implantation w/o DF test, ICD implantation with DF test
- Where
- 2 sites in Germany, Sweden
- Volunteers
- 1,077 people
- Sponsor
- Biotronik SE & Co. KG
Hemophilia A
Non-interventional Observation of Practical Implementation, Efficacy and Safety of Continuous Infusion With KOGENATE Bayer in Surgery
The objective of this international post-marketing surveillance study is to collect data on the efficacy and safety of continuous infusion with KOGENATE Bayer in surgery.
- Trial name
- NO PEACKS (NCT00922597)
- Testing
- Recombinant Factor VIII (Kogenate FS, BAY14-2222)
- Where
- 7 sites in Austria, Germany and 5 more
- Volunteers
- 26 people
- Sponsor
- Bayer
Malignant Solid Tumor, Lymphomas
Safety and Pharmacokinetic Study of RRx-001 in Cancer Subjects
The purpose of this study is to evaluate the safety and pharmacokinetic profile of RRx-001 for injection in subjects with advanced solid tumors or lymphomas for which there are no currently accepted curative therapies.
- Trial name
- DINAMIC (NCT01359982)
- Testing
- RRx-001
- Where
- 2 sites in United States
- Volunteers
- 26 people
- Sponsor
- EpicentRx, Inc.
Primary Neoplasm, Secondary Neoplasm
Nutritional Supplementation in Patients With no Signs of Malnutrition
The aim of the study was to assess the effect of nutritional supplementation on nutritional status and postoperational complications in cancer patients with no clinical signs of malnutrition
- Conditions
- Primary Neoplasm, Secondary Neoplasm, Abdominal Neoplasm
- Trial name
- NCT01894828
- Testing
- Nutritional supplements
- Where
- Poland
- Volunteers
- 200 people
- Sponsor
- MedSource Polska
Intermittent Claudication
Effect of NCX4016 on Walking Distance in Patients With Peripheral Arterial Occlusive Disease (PAOD)
Peripheral arterial disease (PAD) is almost invariably associated with a generalized atherosclerotic involvement of the arterial tree and endothelial dysfunction.
- Trial name
- NCT01256775
- Testing
- NCX-4016
- Where
- Italy
- Volunteers
- 442 people
- Sponsor
- NicOx Research Institute S.r.l.
Hypertension
A Study of the Effects of 6R-BH4 on Blood Pressure in Subjects With Poorly Controlled Systemic Hypertension
The purpose of this study is to determine whether 6R-BH4 (sapropterin dihydrochloride) is safe and effective in the treatment of poorly controlled hypertension in the presence or absence of type 2 diabetes.
- Trial name
- NCT00325962
- Testing
- 6R-BH4 (sapropterin dihydrochloride)
- Where
- 24 sites in United States
- Volunteers
- 84 people
- Sponsor
- BioMarin Pharmaceutical